- Home
- INNV vs IMTX Comparison
INNV vs IMTX Comparison
Compare INNV & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INNV | IMTX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | Germany |
| Employees | N/A | 423 |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | INNV | IMTX |
|---|---|---|
| Price | $7.72 | $9.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $19.00 |
| AVG Volume (30 Days) | 337.0K | ★ 461.8K |
| Earning Date | 05-05-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $853,699,000.00 | N/A |
| Revenue This Year | $12.85 | $1.92 |
| Revenue Next Year | $8.88 | $15.88 |
| P/E Ratio | $59.68 | ★ N/A |
| Revenue Growth | ★ 11.76 | N/A |
| 52 Week Low | $2.60 | $3.30 |
| 52 Week High | $10.69 | $12.41 |
Technical Indicators
Market Signals| Indicator | INNV | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 43.75 |
| Support Level | $5.01 | $9.03 |
| Resistance Level | $9.18 | $10.64 |
| Average True Range (ATR) | 0.63 | 0.59 |
| MACD | -0.22 | -0.06 |
| Stochastic Oscillator | 1.00 | 19.40 |
Price Performance
Historical ComparisonAbout INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.